Interestingly, CD38 targeting did not significantly alter the in vivo growth of NRAS;Ink4a lesions, but the combination of anti-CD38 (αCD38)/αPD-1 significantly reduced tumor growth (Fig. 4D). The gene discussed is CDKN2A; the disease is neoplasm.